Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 319 results for breast cancer

  1. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012 Other

    Research recommendation
    Published
    9 June 2015

  3. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101 Date issued

    Research recommendation
    Published
    11 December 2018

  5. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other

    Research recommendation
    Published
    9 June 2015

  6. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    7 February 2019
    View recommendations

    Sections for NG120

  7. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  8. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

    Medtech innovation briefing
    Published
    20 September 2017

  9. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)

    Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.

    Technology appraisal guidance
    Published
    11 February 2026
    View recommendations

    Sections for TA1130

  10. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

    Technology appraisal guidance
    Last updated
    8 February 2021
    View recommendations

    Sections for TA185

  11. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [GID-TA11987]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 June 2026.

    Technology appraisal guidance
    In consultation

  13. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued

    Research recommendation
    Published
    6 July 2015

  14. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC

    Technology appraisal guidance
    In development